The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment

Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment

October 1, 2020 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

A phase 2b/3 study in Arthritis & Rheumatology highlights the potential of fasinumab, a monoclonal antibody that targets nerve growth factor, to treat osteoarthritis (OA) pain in patients who are unresponsive to or unable to take other therapies.1 Questions remain about the risk/benefit profile of agents in this therapeutic class, but low doses may provide part of the answer.

You Might Also Like
  • Regeneron Pain Drug Clears Late-Stage Trial
  • Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain
  • Many Patients Discontinue Tofacitinib by Year 1; Fasinumab Promising for Pain
Also By This Author
  • ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis

Unmet Need in OA Treatments
Alan J. Kivitz, MD, one of the study’s authors, is president of the Altoona Arthritis and Osteoporosis Center and Altoona Center for Clinical Research and a practicing rheumatologist in Duncansville, Pa. He describes the tremendous need for new OA treatments for patients who are not good candidates for, or respond inadequately to, existing therapies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Over the course of my years of practicing rheumatology, I’ve seen the use of non-steroidal anti-inflammatory drugs [NSAIDs] and cyclo-oxygenase-2 inhibitors that initially had great promise, until some of their significant, potential toxicities were recognized. Therefore, they are often not ideal medications for many of our patients,” he says.

Dr. Kivitz adds, “I’ve also seen how we went through a phase of opioid use, which obviously is now in disfavor because of our current opioid epidemic [in the U.S.]. The major interventions we’ve had in terms of oral medication, systemic medications for treating systemic pain of OA are now not good options for many of our patients.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Nerve Growth Factor & Inhibitors
Nerve growth factor was first observed in the 1950s and recognized for its role in the development of the nervous system. Since that time, its role in the mediation of both acute and chronic pain has increasingly been recognized, including such mechanisms as the sensitization of peripheral nociceptive terminals and the new sprouting of sensory nerves. These mechanisms have made nerve growth factor an attractive target for interventions blocking the nerve growth factor signal.2

However, nervous system cells are not the only ones involved in nerve growth factor signaling. Many non-neuronal cells produce or respond to nerve growth factor, such as chondrocytes and bone cells, potentially complicating side effects profiles of such therapies.1-3

In 2010, the interest in this class of treatments increased after the first well-powered and controlled trial of another anti-nerve growth factor therapy for OA, tanezumab.4 Soon thereafter, however, findings of osteonecrosis and rapidly progressive OA were reported in patients who had received these treatments, and autonomic nervous system damage was noted in preclinical models. These findings prompted the U.S. Food & Drug Administration to place a moratorium on clinical trials of all nerve growth factor antagonists. This moratorium was lifted in 2015, after the enactment of certain research parameters.2,3

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Drug Updates, Osteoarthritis Tagged With: Arthritis & Rheumatology, fasinumab, Knee Osteoarthritis (OA), Nerve growth factor (NGF), osteoarthritis (OA), tanezumab

You Might Also Like:
  • Regeneron Pain Drug Clears Late-Stage Trial
  • Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain
  • Many Patients Discontinue Tofacitinib by Year 1; Fasinumab Promising for Pain
  • Pfizer-Lilly Pain Drug Meets Late-Stage Trial Goals

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)